Guggenheim ABC High Dividend ETF ABCS 深 沪
等待开盘 12-19 09:30:00 美东时间
30.6008
-0.003
-0.01%
华盛通- 最 高30.7884
- 今 开30.68
- 成交量 3206股
- 最 低 30.60
- 昨 收 30.6036
- 总市值 1101.63万
- 52周最高 31.09
- 市盈率 静 --
- 换手率 0.89%
- 52周最低 23.8038
- 委 比 -81.63%
- 总股本 36.00万
- 历史最高 31.09
- 量 比 1.17
- 振 幅 0.62%
- 历史最低 23.7152
- 每 手 1
- 风险率 1.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeoGenomics To Present Data Utilizing Its RaDaR 1.0 Assay For Detection Of Molecular Residual Disease At 2025 SABCS
Data include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and recurrence risk in early breast cancerNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions
12-10 20:09
BriaCell Therapeutics To Present Phase 2 Survival, And Phase 3 Biomarker Data Across Three Clinical Posters At 2025 SABCS
Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus positive key
12-02 20:39
BriaCell Therapeutics To Highlight Phase 2 Safety And Efficacy Signals And Biomarker Findings In Both Phase 2 And Pivotal Phase 3 Studies At 2025 SABCS
Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal
11-25 20:37
BriaCell Therapeutics To Present Three Clinical, One Preclinical Posters At 2025 San Antonio Breast Cancer Symposium
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that
11-18 20:32
调整结束，大反攻开始？
在经历两个多月的调整后，创新药板块再次成为市场焦点。 今天，创新药“纯度”100%的恒生创新药ETF(159316)涨2.52%，低费率的创新药ETF易方达(...
11-12 16:25
Olema Pharmaceuticals To Present A Trial-In-Progress Poster For Its Phase 3 OPERA-02 Trial At 2025 San Antonio Breast Cancer Symposium
Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breastOlema Pharmaceuticals
10-31 04:36
Shark Tank Premieres Wednesday Without Mark Cuban: Reddit Founder, Former NFL Player Among Guest Sharks
Two big changes are coming to the 17th season of "Shark Tank" with the show on a new night and missing long-time shark Mark Cuban.
09-25 04:35
Mark Cuban Bids Farewell To 'Shark Tank': How To Watch Finale And What's Next For Hit Show
Mark Cuban is one of the most loved sharks on "Shark Tank" and one of the most unloved sharks on "Shark Tank." A look back at his time on the hit reality show.
05-17 00:07
TutorABC任命新高管
线上教育、企业培训与直播电商集团 TutorABC，宣布任命George Loup及Maximilian Corbet Smith两位资深人才...
04-08 14:23
"Warner Bros. Discovery Announces 'Olli,' New First-Party Data Platform Powering Converged Audience Solutions"
https://wbd.com/warner-bros-discovery-announces-olli-new-first-party-data-platform-powering-converged-audience-solutions/#:~:text=Warner%20Bros.%20Discovery%20(Nasd
2024-04-25 23:10
